Integra LifeSciences Q3 earnings beat estimates, but revenue falls short
- Integra LifeSciences Holdings Corporation press release (IART): Q3 Non-GAAP EPS of $0.59 beats by $0.03.
- Revenue of $411.2M (+2.3% Y/Y) misses by $0.9M.
Q4 guidance: Revenue of $413M–$433M (vs. consensus of $432.21M) and adjusted diluted EPS of $0.61–$0.71 (vs. consensus of $0.73).
FY2026 guidance: Revenue of $1.634B–$1.654B (vs. consensus of $1.66B) and adjusted diluted EPS of $2.30–$2.40 (vs. consensus of $2.38).
Reported net income was $14.9M, compared with a net loss of $5.4M a year earlier; adjusted net income rose to $46.4M from $41.6M.
Adjusted EBITDA increased to $79.8M from $78.5M, while adjusted gross margin narrowed to 61.1% from 62.9%.
Specialty Surgery revenue rose 3.9% to $304.1M, while Tissue Reconstruction revenue declined 2.2% to $107.1M.
Recommended For You
Create Your Free Account to Keep Reading
Get the confidence to navigate an uncertain market with free breaking news and stock alerts.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.